{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:20:35Z","timestamp":1791181235976,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"CNRS"},{"name":"Aase and Ejnar Danielsen's Foundation"},{"name":"Beckett Foundation"},{"name":"Danish Colitis\u2013Crohn Society"},{"name":"Danish Medical Association Research Foundation"},{"name":"Frode V. Nyegaard and wife's Foundation"},{"name":"Health Science Research Foundation of Region of Copenhagen"},{"name":"Herlev Hospital Research Council"},{"DOI":"10.13039\/501100003554","name":"Lundbeck Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"crossref"}]},{"name":"P. Carl Petersens Foundation"},{"name":"Danish Biotechnology Program"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Immunological Methods"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.jim.2011.08.022","type":"journal-article","created":{"date-parts":[[2011,9,7]],"date-time":"2011-09-07T07:09:40Z","timestamp":1315379380000},"page":"229-239","source":"Crossref","is-referenced-by-count":95,"title":["Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNF\u03b1 antagonists"],"prefix":"10.1016","volume":"373","author":[{"given":"Christophe","family":"Lallemand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Kavrochorianou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casper","family":"Steenholdt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Bendtzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Ainsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Francois","family":"Meritet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Lebon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Alzabin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Tovey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jim.2011.08.022_bb0005","first-page":"571","article-title":"Menstrual and hormonal alterations in juvenile dermatomyositis","volume":"28","author":"Aikawa","year":"2010","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jim.2011.08.022_bb0010","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jim.2011.08.022_bb0015","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1002\/art.22214","article-title":"Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab","volume":"54","author":"Bendtzen","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jim.2011.08.022_bb0020","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1080\/00365520802699278","article-title":"Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies","volume":"44","author":"Bendtzen","year":"2009","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.jim.2011.08.022_bb0025","first-page":"323","article-title":"Involvement of tumour necrosis factor in monocyte-mediated rapid killing of actinomycin D-pretreated WEHI 164 sarcoma cells","volume":"59","author":"Bersani","year":"1986","journal-title":"Immunology"},{"key":"10.1016\/j.jim.2011.08.022_bb0030","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.biologicals.2011.01.006","article-title":"Taking immunogenicity assessment of therapeutic proteins to the next level","volume":"39","author":"Buttel","year":"2011","journal-title":"Biologicals"},{"key":"10.1016\/j.jim.2011.08.022_bb0035","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1056\/NEJMoa011931","article-title":"Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin","volume":"346","author":"Casadevall","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jim.2011.08.022_bb0040","first-page":"40","article-title":"The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis","volume":"25","author":"Dore","year":"2007","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jim.2011.08.022_bb0045","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2249.2008.03773.x","article-title":"Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies","volume":"154","author":"Ebert","year":"2008","journal-title":"Clin. Exp. Immunol."},{"issue":"Suppl. 1","key":"10.1016\/j.jim.2011.08.022_bb0050","doi-asserted-by":"crossref","first-page":"i2","DOI":"10.1136\/ard.2010.146852","article-title":"Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010","volume":"70","author":"Furst","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jim.2011.08.022_bb0055","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1089\/107999001753124471","article-title":"The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit","volume":"21","author":"Grossberg","year":"2001","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.jim.2011.08.022_bb0060","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1089\/107999001753124462","article-title":"The neutralization of interferons by antibody. I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems","volume":"21","author":"Grossberg","year":"2001","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.jim.2011.08.022_bb0065","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1089\/jir.2008.0122","article-title":"Quantification of the neutralization of cytokine biological activity by antibody: the ten-fold reduction bioassay of interleukin-6 as growth factor","volume":"29","author":"Grossberg","year":"2009","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.jim.2011.08.022_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2006.12.004","article-title":"Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics","volume":"321","author":"Gupta","year":"2007","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jim.2011.08.022_bb0075","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2165\/00003495-200464160-00004","article-title":"Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease","volume":"64","author":"Han","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.jim.2011.08.022_bb0080","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0022-1759(03)00203-5","article-title":"Neutralization of the biological activity of cytokines and other protein effectors by antibody: theoretical formulation of antibody titration curves in relation to antibody affinity","volume":"278","author":"Kawade","year":"2003","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jim.2011.08.022_bb0085","author":"Kirshner"},{"key":"10.1016\/j.jim.2011.08.022_bb0090","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1089\/jir.2007.0142","article-title":"Quantification of neutralizing antibodies to human type I interferons using division-arrested frozen cells carrying an interferon-regulated reporter-gene","volume":"28","author":"Lallemand","year":"2008","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.jim.2011.08.022_bb0095","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jim.2010.03.003","article-title":"One-step assay for quantification of neutralizing antibodies to biopharmaceuticals","volume":"356","author":"Lallemand","year":"2010","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jim.2011.08.022_bb0100","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.gtc.2010.08.018","article-title":"Tumor necrosis factor-alpha monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology","volume":"39","author":"Lee","year":"2010","journal-title":"Gastroenterol. Clin. North Am."},{"key":"10.1016\/j.jim.2011.08.022_bb0105","first-page":"218","article-title":"Generation and characterization of a neutralizing rat anti-rmTNF-alpha monoclonal antibody","volume":"71","author":"Lucas","year":"1990","journal-title":"Immunology"},{"key":"10.1016\/j.jim.2011.08.022_bb0110","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1752-8062.2008.00013.x","article-title":"Effect of the soluble TNF-antagonist etanercept on tumor necrosis factor bioactivity and stability","volume":"1","author":"Mann","year":"2008","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.jim.2011.08.022_bb0115","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ymeth.2005.11.005","article-title":"Measurement of cytokines by bioassays: theory and application","volume":"38","author":"Meager","year":"2006","journal-title":"Methods"},{"key":"10.1016\/j.jim.2011.08.022_bb0120","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1128\/IAI.31.1.380-385.1981","article-title":"Rabbit tumor necrosis factor: mechanism of action","volume":"31","author":"Ruff","year":"1981","journal-title":"Infect. Immun."},{"key":"10.1016\/j.jim.2011.08.022_bb0125","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid arthritis","volume":"376","author":"Scott","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jim.2011.08.022_bb0130","author":"Thorpe"},{"key":"10.1016\/j.jim.2011.08.022_bb0135","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.4155\/bio.10.54","article-title":"Unwanted immunogenicity: lessons learned and future challenges","volume":"2","author":"Wadhwa","year":"2010","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jim.2011.08.022_bb0140","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jpba.2007.08.005","article-title":"A non-radioactive method for detecting neutralizing antibodies against therapeutic proteins in serum","volume":"45","author":"Wala","year":"2007","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jim.2011.08.022_bb0145","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/art.21671","article-title":"Development of antiinfliximab page 21 01\/09\/2011 antibodies and relationship to clinical response in patients with rheumatoid arthritis","volume":"54","author":"Wolbink","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jim.2011.08.022_bb0150","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jim.2006.06.016","article-title":"A novel method for detecting neutralizing antibodies against therapeutic proteins by measuring gene expression","volume":"316","author":"Yu","year":"2006","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jim.2011.08.022_bb0155","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.imlet.2007.05.006","article-title":"Investigation of the functional characteristics of antibodies to therapeutic anti-human tumor necrosis factor alpha monoclonal antibody","volume":"111","author":"Yucel","year":"2007","journal-title":"Immunol. Lett."}],"container-title":["Journal of Immunological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175911002407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175911002407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T07:45:05Z","timestamp":1592898305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022175911002407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":31,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0022175911002407"],"URL":"https:\/\/doi.org\/10.1016\/j.jim.2011.08.022","relation":{},"ISSN":["0022-1759"],"issn-type":[{"value":"0022-1759","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}